Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.

Abstract	Development of acquired resistance to gefitinib after an initial good response is common. Recently, it was reported that this acquired resistance is related to a secondary mutation associated with a substitution of threonine by methionine at codon 790 (T790M) of the epidermal growth factor receptor (EGFR) gene. In this report, we present a "never smoking" woman with advanced lung cancer who showed acquired resistance to gefitinib, and analysis of autopsy samples revealed no evidence of EGFR mutations in either exons 18-21 or codon 790, and positive immunostaining for breast cancer resistance protein (BCRP). We describe, for the first time, a case in which expression of BCRP was associated with acquired resistance to gefitinib, independent of EGFR mutations.
Authors	J Usuda, T Ohira, Y Suga, T Oikawa, S Ichinose, T Inoue, K Ohtani, S Maehara, K Imai, M Kubota, Y Tsunoda, H Tsutsui, K Furukawa, T Okunaka, Y Sugimoto, H Kato
Journal	Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 58 Issue 2 Pg. 296-9 (Nov 2007) ISSN: 0169-5002 [Print] Ireland
PMID	17618705 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	ABCG2 protein, human ATP Binding Cassette Transporter, Subfamily G, Member 2 ATP-Binding Cassette Transporters Antineoplastic Agents Neoplasm Proteins Quinazolines Gefitinib
Topics	ATP Binding Cassette Transporter, Subfamily G, Member 2 ATP-Binding Cassette Transporters (genetics) Aged Antineoplastic Agents (therapeutic use) Autopsy Carcinoma, Non-Small-Cell Lung (drug therapy, pathology) Drug Resistance, Neoplasm Fatal Outcome Female Gefitinib Humans Immunohistochemistry Lung Neoplasms (drug therapy, pathology) Neoplasm Proteins (genetics) Quinazolines (pharmacology, therapeutic use) Radiography, Thoracic Smoking Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!